ARS Pharmaceuticals (SPRY) Current Assets (2020 - 2026)

ARS Pharmaceuticals has reported Current Assets for 7 years, with the latest figure at $245.2 million in Q1 2026.

• Quarterly Current Assets fell 19.29% year-over-year to $245.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $245.2 million (down 19.29% YoY) and the FY2025 annual result came in at $284.9 million, down 14.78% from the prior year.
• Current Assets declined to $245.2 million in Q1 2026 per SPRY's latest filing, from $284.9 million in the prior quarter.
• Over five years, Current Assets peaked at $338.9 million in Q3 2025 and troughed at $208.8 million in Q3 2024.
• A 5-year average of $265.6 million and a median of $263.1 million in 2022 frame the typical range for Current Assets.
• The widest YoY moves for Current Assets: up 357.27% in 2022, down 30.93% in 2022.
• Over 5 years, Current Assets stood at $277.7 million in 2022, then declined by 16.56% to $231.7 million in 2023, then jumped by 44.26% to $334.3 million in 2024, then decreased by 14.78% to $284.9 million in 2025, then declined by 13.92% to $245.2 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $245.2 million, $284.9 million, and $338.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.